New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers;Neue antiarrhythmika in der therapie des vorhofflimmerns: II. Nicht-ionenkanalblocker

Herzschrittmachertherapie und Elektrophysiologie

Volumn 17, Issue 2, 2006, Pages 73-80

  Hammwohner M ^a   D'Alessandro, A ^a   Dobrev, D ^b   Kirchhof, P ^c   Goette, A ^a  

^a Klinik fur Kardiologie Angiologie und Pneumologie   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Angiotensin; Atrial fibrillation; Gene therapy; Pathophysiology

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIOXIDANT; ASCORBIC ACID; CALCINEURIN INHIBITOR; CALCIUM CHANNEL L TYPE; CALCIUM ION; CONNEXIN 43; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYOD PROTEIN; OLMESARTAN; RYANODINE RECEPTOR; SIMVASTATIN; TACROLIMUS; UO 126;

ANTIOXIDANT ACTIVITY; CARDIOVERSION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; GENE THERAPY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; GENE THERAPY; HEART CONDUCTION SYSTEM; HUMANS; MODELS, CARDIOVASCULAR; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33745326320     PISSN: 09387412     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00399-006-0513-1     Document Type: Review

References (28)

1. Berk BC (1998) Angiotensin II receptors and angiotensin II-stimulated signal transduction. Heart Failure Rev 3:87-99
2. Brand FN, Abbott RD, Kannel WB, Wolf PA (1985) Characteristics and prognosis of lone atrial fibrillation: 30 years follow-up in the Framingham Study. JAMA 254:3449-3453
3. Bukowska A, Lendeckel U, Hirte D, Wolke C, Striggow F, Rohnert P, Huth C, Klein HU, Goette A (2006) Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. J Cell Mol Life Sci 63:333-342
4. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG, Langberg JJ (2002) Downregulation of nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106:2854-2858
5. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR (2001) Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of post-operative atrial fibrillation. Circulation Res 89:e32-e38
6. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110:2651-2657
7. Francis GS (2000) ACE inhibition in cardiovascular diseases. N Engl J Med 342:201-202
8. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM (1994) Prevalence of atrial fibrillation in elderly subjects. Am J Cardiol 74:236-241
9. Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A (2003) Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 26:295-298
10. Goette A, Lendeckel U (2006) Morphologisches Remodeling bei Vorhofflimmern. Herz 31 (im Druck)
11. Goette A, Honeycutt C, Langberg JJ (1996) Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation 94:2968-2974
12. Goette A, Staack T, Arndt M, Röcken C, Geller C, Huth C, Ansorge S, Klein HU, Lendeckel U (2000) Increased expression of extracellular-signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35:1669-1677
13. Hart RG, Halperin JL (2001) Atrial fibrillation and stroke: concepts and controversies. Stroke 32:803-808
14. Hove-Madsen L, Llach A, Bayes-Genis A, Roura S, Rodriguez Font E, Aris A, Cinca J (2004) Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 110(11):1358-1363
15. Kikuchi K, McDonald AD, Sasano T, Donahue JK (2005) Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation 111:264-270
16. Kim YM, Zhang YH, Guzik TJ, Kattach H, Pillai R, Channon KM, Casadei B (2003) A myocardial nox2 containing NADPH oxidase contributes to oxidative stress in human atrial fibrillation. Circulation 108(Suppl): IV-45 (abstract)
17. Kumagai K, Nakashima H, Gondo N, Saku K (2003) Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol 14:880-884
18. Kizana E, Ginn SL, Allen DG, Ross DL, Alexander IE (2005) Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. Circulation 111:394-398
19. Li D, Fareh S, Leung TK, Nattel S (1999) Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100:87-95
20. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608-2614
21. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331-336
22. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M (2003) Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107:2555-2558
23. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA (2001) Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174-180
24. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219-226
25. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S (2004) Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110:2313-2319
26. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S (2006) Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 69(4):865-875
27. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing hearts. Circ Res 66:883-890
28. Vest JA, Wehrens XH, Reiken SR, Lehnart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, Marks AR (2005) Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111(16):2025-2032